SAN DIEGO, Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avo ...

SAN DIEGO, Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI® (aprepitant) injectable emulsion and SUSTOL® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE® for Postoperative Nausea and Vomiting ("PONV") prevention given the temporary shortage of intravenous ("IV") fluids which is expected as t ...

- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgic ...

Heron Therapeutics, Inc., (NASDAQ:HRTX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Corporate Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer Kevin Warner - SVP of Medical Affairs Strategy and Engagement Conference Call Participants Brandon Folkes - Rodman & Renshaw Serge Belanger - Needham Clara Dong - Jefferies Carl Byrnes - Northland Capital Markets Operator Thank you for standing by. My name is Jermaine, and I will be ...

| --- | --- | --- | |---------------------------------------|-------|-------| | | | | | | | | | Heron Therapeutics Q2 Earnings Call | | | | August 6, 2024 | | | Forward-looking Statements and non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forwardlooking statements are based on management's expectations and assumptions as of the date hereof and are subject to certain risks and uncertain ...

Heron Therapeutics (HRTX) reported $36.02 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 13.4%. EPS of -$0.06 for the same period compares to -$0.35 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $35.35 million, representing a surprise of +1.91%. The company delivered an EPS surprise of -50.00%, with the consensus EPS estimate being -$0.04. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti ...

Financial Performance - Second quarter Net Product Sales reached $36.0 million, up from $31.8 million in the same period of 2023, representing a growth of approximately 6.6%[1] - ZYNRELEF Net Product Sales for Q2 2024 were $5.8 million, an increase from $4.2 million in Q2 2023, reflecting a growth of approximately 38.1%[6] - Oncology Care Franchise Net Product Sales for Q2 2024 were $29.2 million, up from $27.3 million in Q2 2023, indicating a growth of about 7.0%[7] - Acute Care Franchise Net Product Sales for Q2 2024 were $6.8 million, up from $4.5 million in Q2 2023, marking a growth of approximately 51.1%[6] - APONVIE Net Product Sales for Q2 2024 were $1.0 million, an increase from $0.3 million in Q2 2023, reflecting a growth of about 233.3%[6] - Net product sales for Q2 2024 reached $36,024,000, a 13.1% increase from $31,762,000 in Q2 2023[25] - Gross profit for the six months ended June 30, 2024, was $51,732,000, compared to $24,365,000 for the same period in 2023, representing a 112.5% increase[25] - The net loss for Q2 2024 was $9,235,000, significantly lower than the net loss of $42,059,000 in Q2 2023, marking an improvement of 78.1%[25] - Basic and diluted net loss per share improved to $0.06 in Q2 2024 from $0.35 in Q2 2023, a 82.9% reduction in loss per share[25] Expense Management - Adjusted Operating Expenses guidance for 2024 has been narrowed to a range of $107.0 million to $111.0 million, down from the previous range of $108.0 million to $116.0 million[3] - Adjusted EBITDA guidance for 2024 has been revised to a range of $(10.0) million to $3.0 million, improved from the previous range of $(22.0) million to $3.0 million[3] - Total operating expenses decreased to $31,951,000 in Q2 2024 from $54,007,000 in Q2 2023, a reduction of 40.5%[25] Cash and Assets - Cash and cash equivalents decreased to $18,386,000 as of June 30, 2024, down from $28,677,000 at the end of 2023[26] - Accounts receivable increased to $73,708,000 as of June 30, 2024, compared to $60,137,000 at the end of 2023, indicating a 22.5% rise[26] - Total current assets slightly increased to $191,168,000 from $188,774,000 at the end of 2023, reflecting a 0.7% growth[26] - The total liabilities remained relatively stable at $256,076,000 as of June 30, 2024, compared to $256,479,000 at the end of 2023[26] - The accumulated deficit increased to $1,918,409,000 as of June 30, 2024, from $1,906,014,000 at the end of 2023[26] Product Development and Market Strategy - The PDUFA goal date for ZYNRELEF Vial Access Needle (VAN) is set for September 23, 2024, with an anticipated launch before year-end[3] - The training of 561 CrossLink sales representatives for promoting ZYNRELEF to orthopedic surgeons has been completed, supporting increased adoption[4] - ZYNRELEF is included in the proposed 2025 NOPAIN Act, which is expected to maintain separate reimbursement in the HOPD and ASC settings effective April 1, 2025[4]